Appendix II — M — Decisions Cited — M
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
M & K Holdings, Inc. v. Samsung Elecs. Co., 985 F.3d 1376, 2021 USPQ2d 123 (Fed. Cir. 2021) 2128.01
Maas, Ex parte, 9 USPQ2d 1746 (Bd. Pat. App. & Inter. 1987) 2107.03
Maatita, In re, 900 F.3d 1369, 127 USPQ2d 1640 (Fed. Cir. 2018) 1503.02 , 1504.04
Mackay Radio & Tel. Co. v. Radio Corp. of America, 306 U.S. 86, 40 USPQ 199 (1939) 2106.04(a)(1) , 2106.05(b)
MacMillan v. Moffett, 432 F.2d 1237, 167 USPQ 550 (CCPA 1970) 2138.04
Mageli, In re, 470 F.2d 1380, 176 USPQ 305 (CCPA 1973) 716.03(b)
Magerlein, In re, 602 F.2d 366, 202 USPQ 473 (CCPA 1979) 716.02(b)
Magnetics v. Arnold Eng’g Co., 438 F.2d 72, 168 USPQ 392 (7th Cir. 1971) 2133.03(e)(7)
MagSil Corp. v. Hitachi Global Storage Technologies, Inc., 687 F.3d 1377, 103 USPQ2d 1769 (Fed. Cir. 2012) 2161.01 , 2164.06(a)
Mahurkar v. C.R. Bard, Inc., 79 F.3d 1572, 38 USPQ2d 1288 (Fed. Cir. 1996) 2163
Malachowski, In re, 530 F.2d 1402, 189 USPQ 432 (CCPA 1976) 2107.02 , 2107.03
Maldague, In re, 10 USPQ2d 1477 (Comm’r Pat. 1988) 711.03(c)
Maloney, In re, 411 F.2d 1321, 162 USPQ 98 (CCPA 1969) 2144.09
Malvern Panalytical Inc. v. TA Instruments-Waters LLC, 85 F.4th 1365, 2023 USPQ2d 1297 (Fed. Cir. 2023) 2111.01
Mancy, In re, 499 F.2d 1289, 182 USPQ 303 (CCPA 1974) 2116.01
Mann, In re, 861 F.2d 1581, 8 USPQ2d 2030 (Fed. Cir. 1988) 1504.02 , 1504.04 , 2133.03(e)(6)
Mannesmann Demag Corp. v. Engineered Metal Products Co., 793 F.2d 1279, 230 USPQ 45 (Fed. Cir. 1986) 2111.03
Mantell, In re, 454 F.2d 1398, 172 USPQ 530 (CCPA 1972) 715.03
Manville Sales Corp. v. Paramount Sys., Inc., 917 F.2d 544, 16 USPQ2d 1587 (Fed. Cir. 1990) 2133.03 , 2133.03(a)
Marden, In re, 47 F.2d 958, 8 USPQ 347 (CCPA 1931) 2106.04(c)
Margolis, In re, 785 F.2d 1029, 228 USPQ 940 (Fed. Cir. 1986) 716.01(a)
Margolis v. Banner, 599 F.2d 435, 202 USPQ 365 (CCPA 1979) 804.03
Marinissen, Ex parte, 155 USPQ 528, 842 O.G. 528 (Bd. App. 1966) 1504.02
Markush, Ex parte, 1925 C.D. 126, 340 O.G. 839 (Comm’r Pat. 1924) 803.02 , 2117 , 2173.05(h)
Marosi, In re, 710 F.2d 799, 218 USPQ 289 (Fed. Cir. 1983) 2111.01 , 2113 , 2158.01 , 2173.05(b) , 2173.05(g)
Mars Inc. v. H.J. Heinz Co., 377 F.3d 1369, 71 USPQ2d 1837 (Fed. Cir. 2004) 2111.03
Marsh Eng’g Co., In re, 1913 C.D. 183 (Comm’r Pat. 1913) 103
Martin, In re, 154 F.2d 126, 69 USPQ 75 (CCPA 1946) 1211.03
Martin v. Johnson, 454 F.2d 746, 172 USPQ 391 (CCPA 1972) 2163 , 2173.05(t)
Martin v. Mayer, 823 F.2d 500, 3 USPQ2d 1333 (Fed. Cir. 1987) 2163
Marzocchi, In re, 439 F.2d 220, 169 USPQ 367 (CCPA 1971) 2107.01 , 2107.02 , 2124 , 2163 , 2163.04 , 2164.03 , 2164.04 , 2164.08
Masco Corp. v. United States, 303 F.3d 1316, 64 USPQ2d 1182 (Fed. Cir. 2002) 2181
Masham, Ex parte, 2 USPQ2d 1647 (Bd. Pat. App. & Inter. 1987) 2114
Mas-Hamilton Group v. LaGard, Inc., 156 F.3d 1206, 48 USPQ2d 1010 (Fed. Cir. 1998) 2181
Massachusetts Institute of Technology v. A.B. Fortia, 774 F.2d 1104, 227 USPQ 428 (Fed. Cir. 1985) 2128.01 , 2152.02(e) , 2164.01
Massachusetts Institute of Technology and Electronics For Imaging, Inc. v. Abacus Software, 462 F.3d 1344, 80 USPQ2d 1225 (Fed. Cir. 2006) 2173.01 , 2181
Mastermine Software, Inc. v. Microsoft Corp., 874 F.3d 1307, 124 USPQ2d 1618 (Fed. Cir. 2017) 2173.05(p)
Mathews, In re, 408 F.2d 1393, 161 USPQ 276 (CCPA 1969) 715.01(c) , 2136.04 , 2136.05
Mattison, In re, 509 F.2d 563, 184 USPQ 484 (CCPA 1975) 2173.05(b) , 2173.05(c)
Mattor v. Coolegem, 530 F.2d 1391, 189 USPQ 201 (CCPA 1976) 2109
Mattson, In re, 208 USPQ 168 (Comm’r Pat. 1980) 601.01(e)
Mattullath, In re, 38 App. D.C. 497 (1912) 2734
Maucorps, In re, 609 F.2d 481, 203 USPQ 812 (CCPA 1979) 2106.04(a)(1) , 2184
May, In re, 574 F.2d 1082, 197 USPQ 601 (CCPA 1978) 716.02(c) , 1207.03(a) , 2112.02 , 2144.08 , 2144.09
Mayewsky, In re, 860 F.2d 430, 162 USPQ 86 (E.D. Va. 1969) 1701.01
Mayhew, In re, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976) 2163 , 2163.05 , 2164.08(c) , 2172.01 , 2174
Mayne, In re, 104 F.3d 1339, 41 USPQ2d 1451 (Fed. Cir. 1977) 2144.09 , 2145
Mayo Collaborative Services v. Prometheus Labs., Inc., 566 U.S. 66, 101 USPQ2d 1961 (2012) 2106 , 2106.04 , 2106.04(a)(1) , 2106.04(a)(2) , 2106.04(b) , 2106.05 , 2106.05(c) , 2106.05(d) , 2106.05(f) , 2106.05(g) , 2106.05(h) , 2106.06 , 2106.07(b)
Mayo Found. for Med. Educ. & Research v. Iancu, 938 F.3d 1343, 2019 USPQ2d 346079 (Fed. Cir. 2019) 2731
Mazer v. Stein, 347 U.S. 201, 100 USPQ 325 (1954) 1512
Maziere, Ex parte, 27 USPQ2d 1705 (Bd. Pat. App. & Inter. 1993) 608.01(p)
MBO Laboratories, Inc. v. Becton, Dickinson & Co., 602 F.3d 1306, 94 USPQ2d 1598 (Fed. Cir. 2010) 1412.02
McCulloch Gas Processing Co. v. Dept. of Energy, 650 F.2d 1216 (Temp. Emer. Ct. App. 1981) 1701.01
McAward, Ex parte, Appeal 2015-006416 (PTAB Aug. 25, 2017) 2173.02
McCullough, Ex parte, 7 USPQ2d 1889 (Bd. Pat. App. & Inter. 1987) 2145
McDaniel, In re, 293 F.3d 1379, 63 USPQ2d 1462 (Fed. Cir. 2002) 1205.02
McDonald, In re, 43 F.4th 1340, 2022 USPQ2d 745 (Fed. Cir. 2022) 1412.02
McGaughey, Ex parte, 6 USPQ2d 1334 (Bd. Pat. App. & Inter. 1988) 2217 , 2258
McGrady v. Aspenglas Corp., 487 F. Supp 859, 208 USPQ 242 (S.D. N.Y. 1981) 1503.01 , 1504.01(a)
McGrew, In re, 120 F.3d 1236, 43 USPQ2d 1632 (Fed. Cir. 1997) 715.05 , 2304.02(c)
McKellin, In re, 529 F.2d 1342, 188 USPQ 428 (CCPA 1976) 715
McKenna, In re, 203 F.2d 717, 97 USPQ 348 (CCPA 1953) 716.01(c)
McLaughlin, In re, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971) 707.07(f) , 2145
McNeil-PPC, In re, 574 F.3d 1393, 91 USPQ2d 1576 (Fed. Cir. 2009) 1214.01
McRO, Inc. v. Bandai Namco Games America, Inc. 837 F.3d 1299, 120 USPQ2d 1091 (Fed. Cir. 2016) 2106 , 2106.04 , 2106.04(a) , 2106.04(a)(1) , 2106.04(a)(2) , 2106.05 , 2106.05(a) , 2106.05(b) , 2106.05(c) , 2106.05(f) , 2106.06(b)
McRO, Inc. v. Bandai Namco Games Am. Inc., 959 F.3d 1091, 2020 USPQ2d 10550 (Fed. Cir. 2020) 2164.01(a) , 2164.08
Mead, In re, 581 F.2d 251, 198 USPQ 412 (CCPA 1978) 1412.01
Mead Johnson & Co., Ex parte, 227 USPQ 78 (Bd. Pat. App. & Inter. 1985) 716.02(a)
Mead Johnson Pharmaceutical Group v. Bowen, 838 F.2d 1332, 6 USPQ2d 1565 (DC Cir. 1988) 2754.01
Media Rights Technologies, Inc. v. Capital One Financial Corp., 800 F.3d 1366, 116 USPQ2d 1144 (Fed. Cir. 2015) 2181
Medical Instrumentation & Diagnostics Corp. v. Elekta AB, 344 F.3d 1205, 68 USPQ2d 1263 (Fed. Cir. 2003) 2181 , 2182
Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157, 77 USPQ2d 1865 (Fed Cir. 2006) 2141.02 , 2143.01
Medicines Co. v. Hospira, Inc., 827 F.3d 1363, 119 USPQ2d 1329 (Fed. Cir. 2016) 2133.03(b)
Medrad, Inc. v. MRI Devices Corp., 401 F.3d 1313, 74 USPQ2d 1184 (Fed. Cir. 2005) 2173.02
Medrad, Inc. v. Tyco Healthcare Group LP, 466 F.3d 1047, 80 USPQ2d 1526 (Fed. Cir. 2006) 1402
Medtronic, Inc. v. Barry, 891 F.3d 1368, 127 USPQ2d 1208 (Fed. Cir. 2018) 2128
Medtronic, Inc. v. Cardiac Pacemakers, 721 F.2d 1563, 220 USPQ 97 (Fed. Cir. 1983) 2141.01(a)
Mehta, Ex parte, Appeal No. 2000-0160 (Bd. Pat. App. & Inter. 2002) 2172.01
Meitzner v. Corte, 537 F.2d 524, 190 USPQ 407 (CCPA 1976) 2138.05
Mendenhall v. Cedarapids, Inc., 5 F.3d 1557, 28 USPQ2d 1081 (Fed. Cir. 1993) 211.05
Mentor Corp. v. Coloplast, Inc., 998 F.2d 992, 27 USPQ2d 1521 (Fed. Cir. 1993) 1412.02
Mentor Graphics v. EVE-USA, Inc., 851 F.3d 1275, 112 USPQ2d 1120 (Fed. Cir. 2017) 2106 , 2106.03 , 2106.04(a)(2)
Merchant, In re, 575 F.2d 865, 197 USPQ 785 (CCPA 1978) 716.02(e)
Merck & Cie v. Gnosis S.p.A., 808 F.3d 829, 117 USPQ2d 1393 (Fed. Cir. 2015) 716.03(b)
Merck & Co., Inc. In re, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986) 2141.03
Merck & Co. v. Biocraft Laboratories, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir. 1989) 716.02(a) , 2123 , 2144.05 , 2144.08
Merck & Co., Inc., In re, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986) 707.07(f) , 716.02 , 2143.02 , 2144.08 , 2144.09 , 2145
Merck & Co., Inc. v. Hi-Tech Pharmacal, Co., Inc., 482 F.3d 1317, 82 USPQ2d 1203 (Fed. Cir. 2007) 804.05 , 2701 , 2751
Merck & Co. v. Teva Pharms. USA, Inc., 395 F.3d 1364, 73 USPQ2d 1641 (Fed. Cir. 2005) 2111.01
Mergenthaler v. Scudder, 11 App. D.C., 1897 C.D. 724, 81 O.G. 1417 (D.C. Cir. 1897) 715 , 715.07 , 2146.02
Messick, Ex parte, 7 USPQ 57, 1930 C.D. 6, 400 O.G. 3 (Comm’r Pat.1930) 710.01(a)
Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 71 USPQ2d 1081 (Fed. Cir. 2004) 2111.02 , 2112
Metcalfe, In re, 410 F.2d 1378, 161 USPQ 789 (CCPA 1969) 608.01(v) , 2404.01
Metropolitan Eng. Co. v. Coe, 78 F.2d 199, 25 USPQ 216 (D.C. Cir. 1935) 716.07
Meyer, Ex parte, 6 USPQ2d 1966 (Bd. Pat. App. & Inter. 1988) 2145
Meyer, In re, 599 F.2d 1026, 202 USPQ 175 (CCPA 1979) 2131.02
Meyer, In re, 688 F.2d 789, 215 USPQ 193 (CCPA 1982) 2106.04(a)(2) , 2184
Meyers, In re, 688 F.2d 789, 215 USPQ 193 (CCPA 1982) 2106.05(g)
Michalek, In re, 162 F.2d 229, 74 USPQ 107 (CCPA 1947) 716.07
Micro Chemical, Inc. v. Great Plains Chemical Co., 103 F.3d 1538, 41 USPQ2d 1238 (Fed. Cir. 1997) 2133.03(b)
Microsoft Corp. v. AT&T Corp., 550 U.S. 437, 82 USPQ2d 1400 (2007) 2106.03 , 2106.04(a)(2)
Midwest Indus., Inc. v. Karavan Trailers, Inc., 175 F.3d 1356, 50 USPQ2d 1672 (Fed. Cir. 1999) 716.03(b) , 716.06
Milburn v. Davis-Bournonville Co., 270 U.S. 390, 46 S. Ct. 324, 1926 C.D. 303, 344 O.G. 817 (1926) 2136.04
Miles Labs. Inc. v. Shandon Inc., 997 F.2d 870, 27 USPQ2d 1123 (Fed. Cir. 1993) 716.01(a)
Miller, In re, 418 F.2d 1392, 164 USPQ 46 (CCPA 1969) 2111.05 , 2112.01
Miller, In re, 441 F.2d 689, 169 USPQ 597 (CCPA 1971) 2143.03 , 2173.04
Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894) 804 , 804.01 , 804.02
Mills, In re, 281 F.2d 218, 126 USPQ 513 (CCPA 1960) 2144.09
Mills, In re, 916 F.2d 680, 16 USPQ2d 1430 (Fed. Cir. 1990) 2144.08
Milton, Ex parte, 63 USPQ 132 (P.O. Super. Exam. 1938) 710.04(a)
Minerals Separation, Ltd. v. Hyde, 242 U.S. 261 (1916) 2144.05 , 2164.01
Minton v. Natl. Ass’n. of Securities Dealers, Inc., 336 F.3d 1373, 67 USPQ2d 1614 (Fed. Cir. 2003) 2106.03 , 2111.04 , 2133.03(c)
Miyazaki, Ex parte, 89 USPQ2d 1207 (Bd. Pat. App. & Inter. 2008) 2173.05(b)
Mlot-Fijalkowski, In re, 676 F.2d 666, 213 USPQ 713 (CCPA 1982) 2141.01(a)
Moba, B.V. v. Diamond Automation, Inc., 325 F.3d 1306, 66 USPQ2d 1429 (Fed. Cir. 2003) 2163
Mochel, In re, 470 F.2d 638, 176 USPQ 194 (CCPA 1974) 2173.05(c)
Mogen David Wine Corp., In re, 328 F.2d 925, 140 USPQ 575 (CCPA 1964) 1512
Mohsenzadeh v. Lee, 115 USPQ2d 1483 (Fed. Cir. 2015) 2732
Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 229 USPQ 805 (Fed. Cir. 1986) 2111.03 , 2133.03(a) , 2133.03(b)
Moler v. Purdy, 131 USPQ 276 (Bd. Pat. Inter. 1960) 2109.01
Molins, In re, 368 F.2d 258, 151 USPQ 570 (CCPA 1966) 1449.02
Molins PLC v. Textron Inc., 48 F.3d 1172, 33 USPQ2d 1823 (Fed. Cir. 1995) 2004
Monks, In re, 588 F.2d 308, 200 USPQ 129 (CCPA 1978) 1504 , 2126.01 , 2135.01
Monogram Mfg. v. F. & H. Mfg., 144 F.2d 412, 62 USPQ 409 (9th Cir. 1944) 2133.03(e)(1)
Monsanto Co. v. Kamp, 269 F. Supp 818, 154 USPQ 259 (D.D.C. 1967) 602.09
Monsanto Co. v. Mycogen Plant Sci., Inc., 261 F.3d 1356, 59 USPQ2d 1930 (Fed. Cir. 2001) 2138.06
Moore, In re, 439 F.2d 1232, 169 USPQ 236 (CCPA 1971) 1504.04 , 2161.01 , 2164.08 , 2172 , 2173.03
Moore, In re, 444 F.2d 572, 170 USPQ 260 (CCPA 1971) 715.07
Moore v. U.S., 194 USPQ 423 (Ct. Cl. 1977) 2134
Morehouse, In re, 545 F.2d 162, 192 USPQ 29 (CCPA 1976) 2164.06(c)
Moreton, In re, 288 F.2d 708, 129 USPQ 227 (CCPA 1961) 2121 , 2173.05(q)
Morgan, In re, 990 F.2d 1230, 26 USPQ2d 1392 (Fed. Cir. 1993) 1415.01 , 1443
Morganroth v. Quigg, 885 F.2d 843, 12 USPQ2d 1125 (Fed. Cir. 1989) 1216.01 , 2308.04
Morris, In re, 127 F.3d 1048, 44 USPQ2d 1023 (Fed. Cir. 1997) 904.01 , 2111 , 2111.01 , 2163 , 2173.01 , 2173.02 , 2173.05(a) , 2181
Morsa, In re, 713 F.3d 104, 106 USPQ2d 1327 (Fed. Cir. 2013) 2121
Morse v. Porter, 155 USPQ 280 (Bd. Pat. Inter. 1965) 2109
Mortgage Grader, Inc. v. First Choice Loan Servs., 811 F.3d. 1314, 117 USPQ2d 1693 (Fed. Cir. 2015) 2106.04(a)(2)
Morton, Ex parte, 134 USPQ 407 (Bd. App. 1961) 2173.05(t)
Morton Int’l, Inc. v. Cardinal Chem. Co., 5 F.3d 1464, 28 USPQ2d 1190 (Fed. Cir. 1993) 2173.02
Morway v. Bondi, 203 F.2d 742, 97 USPQ 318 (CCPA 1953) 2138.06
Mosher, In re, 248 F.2d 956, 115 USPQ 140 (CCPA 1957) 1216.01
Mostafazadeh, In re, 643 F.3d 1353, 98 USPQ2d 1639 (Fed. Cir. 2011) 1412.01 , 1412.02
Mott, In re, 539 F.2d 1291, 190 USPQ 536 (CCPA 1976) 804 , 2181
Mouttet, In re, 686 F.3d 1322, 103 USPQ2d 1219 (Fed. Cir. 2012) 2145
Mowry, Ex parte, 91 USPQ 219 (Bd. App. 1950) 2144.09
Mowry v. Whitney, 81 U.S. (14 Wall.) 620 (1871) 2164.07
Mraz, In re, 455 F.2d 1069, 173 USPQ 25 (CCPA 1972) 2125
MRC Innovations, Inc. v. Hunter Mfg., LLP, 747 F.3d 1326, 110 USPQ2d 1235 (Fed. Cir. 2014) 1504.03
Mulder, In re, 716 F.2d 1542, 219 USPQ 189 (Fed. Cir. 1983) 2138.06 , 2183 , 2184
Multiform Desiccants Inc. v. Medzam Ltd., 133 F.3d 1473, 45 USPQ2d 1429 (Fed. Cir. 1998) 2111.01
Multilayer Stretch Cling Film Holdings, Inc. v. Berry Plastics Corp., 831 F.3d 1350, 119 USPQ2d 1773 (Fed. Cir. 2016) 803.02 , 2111.03 , 2117
Multiple Litigation Involving Frost Patent, In re, 540 F.2d 601, 191 USPQ 241 (3d Cir. 1976) 2016
Munchkin, Inc. v. Luv N’ Care, Ltd., 110 USPQ2d 1580 (P.T.A.B. 2014) 1504.04
Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318, 87 USPQ2d 1350 (Fed. Cir. 2008) 2114 , MPEP § 2143
Musgrave, In re, 431 F.2d 882, 167 USPQ 280 (CCPA 1970) 2173.05(b)
Cited authority
- 2128.01 Level of Public Accessibility Required
- 2107.03 Special Considerations for Asserted Therapeutic or Pharmacological Utilities
- 1503.02 Drawing
- 1504.04 Considerations Under 35 U.S.C. 112
- 2106.04(a)(2) Abstract Idea Groupings
- 2106.05(b) Particular Machine
- 2138.04 “Conception”
- 716.03(b) Commercial Success Derived From Claimed Invention
- 716.02(b) Burden on Applicant
- 2133.03(e)(7) Activity of an Independent Third Party Inventor
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2164.06(a) Examples of Enablement Issues-Missing Information
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 2107.02 Procedural Considerations Related to Rejections for Lack of Utility
- 711.03(c) Petitions Relating to Abandonment
- 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers)
- 2111.01 Plain Meaning
- 2116.01 Novel, Nonobvious Starting Material or End Product
- 1504.02 Novelty
- 2133.03(e)(6) Permitted Experimental Activity and Testing
- 2111.03 Transitional Phrases
- 715.03 Genus-Species, Practice Relative to Cases Where Predictability Is in Question
- 2133.03 Rejections Based on “Public Use” or “On Sale”
- 2133.03(a) “Public Use”
- 2106.04(c) The Markedly Different Characteristics Analysis
- 716.01(a) Objective Evidence of Nonobviousness
- 804.03 Commonly Owned Inventions of Different Inventive Entities; Non-Commonly Owned Inventions Subject to a Joint Research Agreement
- 803.02 Election of Species Requirements – Markush Claims
- 2117 Markush Claims
- 2173.05(h) Alternative Limitations
- 2113 Product-by-Process Claims
- 2158.01 Form Paragraphs for Use in Rejections Under AIA 35 U.S.C. 103
- 2173.05(b) Relative Terminology
- 2173.05(g) Functional Limitations
- 103 Right of Public To Inspect Patent Files and Some Application Files
- 1211.03 Remand To Consider Affidavits or Declarations
- 2173.05(t) Chemical Formula
- 2107.01 General Principles Governing Utility Rejections
- 2124 Exception to the Rule That the Reference Must be Prior Art
- 2163.04 Burden on the Examiner with Regard to the Written Description Requirement
- 2164.03 Relationship of Predictability of the Art and the Enablement Requirement
- 2164.04 Burden on the Examiner Under the Enablement Requirement
- 2164.08 Enablement Commensurate in Scope With the Claims
- 2181 Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation
- 2114 Apparatus and Article Claims — Functional Language
- 2152.02(e) Otherwise Available to the Public
- 2164.01 Test of Enablement
- 2173.01 Interpreting the Claims
- 2173.05(p) Claim Directed to Product-By- Process or Product and Process
- 715.01(c) Reference Is Publication of Inventor’s Own Invention
- 2136.04 Different Inventive Entity; Meaning of “By Another”
- 2136.05 Overcoming a Rejection Under Pre-AIA 35 U.S.C. 102(e)
- 2173.05(c) Numerical Ranges and Amounts Limitations
- 2109 Inventorship
- 601.01(e) Nonprovisional Application Filed Without at Least One Claim
- 2734 Application for Patent Term Adjustment; Due Care Showing
- 2184 Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made
- 716.02(c) Weighing Evidence of Expected and Unexpected Results
- 1207.03(a) Determining Whether a Ground of Rejection is New
- 2112.02 Process Claims
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 1701.01 Office Personnel Not To Testify
- 2163.05 Changes to the Scope of Claims
- 2164.08(c) Critical Feature Not Claimed
- 2172.01 Unclaimed Essential Subject Matter
- 2174 Relationship Between the Requirements of 35 U.S.C. 112(a) and (b) or Pre-AIA 35 U.S.C. 112, First and Second Paragraphs
- 2145 Consideration of Applicant’s Rebuttal Arguments and Evidence
- 2106 Patent Subject Matter Eligibility
- 2106.04 Eligibility Step 2A: Whether a Claim is Directed to a Judicial Exception
- 2106.04(a)(1) Examples of Claims That Do Not Recite Abstract Ideas
- 2106.04(b) Laws of Nature, Natural Phenomena & Products of Nature
- 2106.05 Eligibility Step 2B: Whether a Claim Amounts to Significantly More
- 2106.05(c) Particular Transformation
- 2106.05(d) Well-Understood, Routine, Conventional Activity
- 2106.05(f) Mere Instructions To Apply An Exception
- 2106.05(g) Insignificant Extra-Solution Activity
- 2106.05(h) Field of Use and Technological Environment
- 2106.06 Streamlined Analysis
- 2106.07(b) Evaluating Applicant’s Response
- 2731 Period of Adjustment
- 1512 Relationship Between Design Patent, Copyright, and Trademark
- 608.01(p) Completeness of Specification
- 1412.02 Recapture of Canceled Subject Matter
- 2173.02 Determining Whether Claim Language is Definite
- 1205.02 Appeal Brief Content
- 2217 Statement Applying Prior Art in a Request Filed under 35 U.S.C. 302
- 2258 Scope of Ex Parte Reexamination
- 1503.01 Specification
- Title Page Title Page
- 715.05 U.S. Patent or Application Publication Claiming Same Invention
- 2304.02(c) Explaining Priority
- 715 Swearing Behind a Reference — Affidavit or Declaration Under 37 CFR 1.131(a)
- 716.01(c) Probative Value of Objective Evidence
- 707.07(f) Answer All Material Traversed
- 1214.01 Procedure Following New Ground of Rejection by Board
- 2106.04(a) Abstract Ideas
- 2106.05(a) Improvements to the Functioning of a Computer or To Any Other Technology or Technical Field
- 2106.06(b) Clear Improvement to a Technology or to Computer Functionality
- 2164.01(a) Undue Experimentation Factors
- 1412.01 Reissue Claims Must Be for Same General Invention
- 716.02(a) Evidence Must Show Unexpected Results
- 2754.01 Deadline for Filing an Application Under 35 U.S.C. 156(d)(1)
- 2182 Search and Identification of the Prior Art
- 2141.02 Differences Between Prior Art and Claimed Invention
- 2143.01 Suggestion or Motivation To Modify the References
- 2133.03(b) “On Sale”
- 1402 Grounds for Filing
- 2128 “Printed Publications” as Prior Art
- 2141.01(a) Analogous and Nonanalogous Art
- 2138.05 “Reduction to Practice”
- 211.05 Sufficiency of Disclosure in Prior-Filed Application
- 2106.03 Eligibility Step 1: The Four Categories of Statutory Subject Matter
- 716.02(e) Comparison With Closest Prior Art
- 2141.03 Level of Ordinary Skill in the Art
- 2123 Rejection Over Prior Art’s Broad Disclosure Instead of Preferred Embodiments
- 2144.05 Obviousness of Similar and Overlapping Ranges, Amounts, and Proportions
- 716.02 Allegations of Unexpected Results
- 2143.02 Reasonable Expectation of Success Is Required
- 804.05 Impact of Patent Term Extension under 35 U.S.C. 156 on Nonstatutory Double Patenting
- 2701 Patent Term
- 2751 Eligibility Requirements
- 715.07 Facts and Documentary Evidence
- 2146.02 Establishing Common Ownership or Joint Research Agreement Under Pre-AIA 35 U.S.C. 103(c)
- 710.01(a) Statutory Period, How Computed
- 2111.02 Effect of Preamble
- 2112 Requirements of Rejection Based on Inherency; Burden of Proof
- 608.01(v) Marks Used in Commerce and Trade Names
- 2404.01 Biological Material That Is Known and Readily Available to the Public
- 716.07 Inoperability of References
- 2131.02 Genus-Species Situations
- 716.06 Copying
- 2111.05 Functional and Nonfunctional Descriptive Material
- 2112.01 Composition, Product, and Apparatus Claims
- 2143.03 All Claim Limitations Must Be Considered
- 2173.04 Breadth Is Not Indefiniteness
- 804 Definition of Double Patenting
- 804.01 Prohibition of Nonstatutory Double Patenting Rejections Under 35 U.S.C. 121
- 804.02 Avoiding a Double Patenting Rejection
- 710.04(a) Copying Patent Claims
- 2111.04 “Adapted to,” “Adapted for,” “Wherein,” “Whereby,” and Contingent Clauses
- 2133.03(c) The “Invention”
- 2732 Reduction of Period of Adjustment of Patent Term
- 1449.02 Interference in Reissue
- 2004 Aids to Compliance With Duty of Disclosure
- 1504 Examination
- 2126.01 Date of Availability of a Patent as a Reference
- 2135.01 The Four Requirements of Pre-AIA 35 U.S.C. 102(d)
- 2133.03(e)(1) Commercial Exploitation
- 602.09 Joint Inventors
- 2138.06 “Reasonable Diligence”
- 2172 Subject Matter Which the Inventor or a Joint Inventor Regards as The Invention
- 2173.03 Correspondence Between Specification and Claims
- 2134 Pre-AIA 35 U.S.C. 102(c)
- 2164.06(c) Examples of Enablement Issues – Computer Programming Cases
- 2121 Prior Art; General Level of Operability Required to Make a Prima Facie Case
- 2173.05(q) “Use” Claims
- 1415.01 Maintenance Fees on the Original Patent
- 1443 Initial Examiner Review
- 1216.01 Appeals to the U.S. Court of Appeals for the Federal Circuit
- 2308.04 Office Procedure Following Decision by the U. S. Court of Appeals for the Federal Circuit
- 904.01 Analysis of Claims
- 2111 Claim Interpretation; Broadest Reasonable Interpretation
- 2173.05(a) New Terminology
- 2164.07 Relationship of Enablement Requirement to Utility Requirement of 35 U.S.C. 101
- 2125 Drawings as Prior Art
- 1504.03 Nonobviousness
- 2183 Making a Prima Facie Case of Equivalence
- 2016 Fraud, Inequitable Conduct, or Violation of Duty of Disclosure Affects All Claims
- 2143 Examples of Basic Requirements of a Prima Facie Case of Obviousness